Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27542697 | 0.88 | PTGDR2 (0.64) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL3480872 | 0.86 | PTGDR2 (0.69) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL31534614 | 0.84 | RAB9A (0.55) | MAPTTDP1HSD17B10ALDH1A1LMNA | |
| SCHEMBL31324800 | 0.83 | PTGDR2 (0.62) | PTGDR2MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10896752 | 0.83 | PTGDR2 (0.62) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL13215131 | 0.82 | POLB (0.52) | MAPTTDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16095891 | 0.82 | PTGDR2 (0.60) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL6921762 | 0.81 | PTGDR2 (0.63) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL1531280 | 0.81 | PTGDR2 (0.63) | PTGDR2MAPTTDP1ALDH1A1LMNA | |
| SCHEMBL10788762 | 0.80 | MEN1 (0.66) | PTGDR2MAPTTDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185562-B1 | PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-02 | — | — | EP | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-2185562-A1 | PYRROLOPYRIMIDINES | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016132-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | PTGDR2 1627/4885MAPT 2102/4885TDP1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.